Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy.

Literature DB >> 31664715

A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy.

J Kevin Hicks¹, Jeffrey R Bishop², Roseann S Gammal^3,4, Katrin Sangkuhl⁵, Chad A Bousman^6,7,8, J Steven Leeder⁹, Adrián Llerena^10,11, Daniel J Mueller^12,13, Laura B Ramsey^14,15, Stuart A Scott^16,17, Todd C Skaar¹⁸, Kelly E Caudle⁴, Teri E Klein⁵, Andrea Gaedigk⁹.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2019 PMID： 31664715 PMCID： PMC6925627 DOI： 10.1002/cpt.1661

Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875

× No keyword cloud information.

7 in total

Review 1. Concentration-Effect Relationships of Psychoactive Drugs and the Problem to Calculate Therapeutic Reference Ranges.

Authors: Christoph Hiemke
Journal: Ther Drug Monit Date: 2019-04 Impact factor: 3.681

2. Venlafaxine or a second SSRI: Switching after treatment failure with an SSRI among depressed inpatients: a retrospective analysis.

Authors: Yoram Barak; Marnina Swartz; Yehuda Baruch
Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2011-06-24 Impact factor: 5.067

Review 3. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.

Authors: J K Hicks; J R Bishop; K Sangkuhl; D J Müller; Y Ji; S G Leckband; J S Leeder; R L Graham; D L Chiulli; A LLerena; T C Skaar; S A Scott; J C Stingl; T E Klein; K E Caudle; A Gaedigk
Journal: Clin Pharmacol Ther Date: 2015-06-29 Impact factor: 6.875

4. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.

Authors: Marin M Jukić; Tore Haslemo; Espen Molden; Magnus Ingelman-Sundberg
Journal: Am J Psychiatry Date: 2018-01-12 Impact factor: 18.112

5. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.

Authors: J K Hicks; K Sangkuhl; J J Swen; V L Ellingrod; D J Müller; K Shimoda; J R Bishop; E D Kharasch; T C Skaar; A Gaedigk; H M Dunnenberger; T E Klein; K E Caudle; J C Stingl
Journal: Clin Pharmacol Ther Date: 2017-02-13 Impact factor: 6.875

6. Emergency department visits by adults for psychiatric medication adverse events.

Authors: Lee M Hampton; Matthew Daubresse; Hsien-Yen Chang; G Caleb Alexander; Daniel S Budnitz
Journal: JAMA Psychiatry Date: 2014-09 Impact factor: 21.596

7. Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.

Authors: Stacey L Aldrich; Ethan A Poweleit; Cynthia A Prows; Lisa J Martin; Jeffrey R Strawn; Laura B Ramsey
Journal: Front Pharmacol Date: 2019-02-19 Impact factor: 5.810

7 in total

5 in total

A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy.

Review 1. Concentration-Effect Relationships of Psychoactive Drugs and the Problem to Calculate Therapeutic Reference Ranges.

2. Venlafaxine or a second SSRI: Switching after treatment failure with an SSRI among depressed inpatients: a retrospective analysis.

Review 3. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.

4. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.

5. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.

6. Emergency department visits by adults for psychiatric medication adverse events.

7. Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.

Review 1. Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.

2. Comparison of clinical pharmacogenetic recommendations across therapeutic areas.

3. Pharmacogenetic testing among patients with depression in a US managed care population.

4. Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy.

5. A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression.